When to Conduct Hepatic Impairment Studies and When Modeling May be Enough
How to decide if a hepatic impairment study is required, choose the right study design,…
CertaraJuly 13, 2026
Dosimetry tells you the dose. It doesn’t tell you the decision.
Learn why absorbed dose data alone isn't enough for radiopharmaceutical dose optimization, and how BED,…
CertaraJuly 7, 2026
Enhancing clinical trials with real-world evidence in pregnancy research
Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…
CertaraJune 26, 2026
How to Build a Best Practice Global Value Dossier With a Decision-first Strategy
Learn how a decision-first approach to value dossier preparation helps teams build pharma value dossiers…
CertaraJune 25, 2026
Development of a human PBMC TXG-MAPr as a mechanistic framework to interpret toxicodynamic variability across the human population
Leiden University and EFSA researchers present the PBMC TXG-MAPr — a network-based transcriptomic tool mapping…
CertaraJune 23, 2026
Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteers
Research from Leiden University and EFSA characterizing interindividual toxicodynamic variability using peripheral blood mononuclear cells…
CertaraJune 23, 2026
Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development
Integrated offering combines drug development, regulatory, commercial, and investor strategy expertise to help early-stage biotech…
Danielle PillsburyJune 23, 2026
Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies
Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…
CertaraJune 23, 2026
